[药剂师对炎症性肠病的门诊服务的有用性]
Ikkou Hirata1,2, Ryohkan Funakoshi2
1Department of Pharmacy, Kameda Clinic.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
|November 1, 2023
概括
门诊药剂师显著改善炎症性肠病 (IBD) 治疗结果. 他们在IBD诊所的干预措施被医生高度接受,导致更好的患者结果和成本效益.
科学领域:
- 胃肠病学 胃肠病学
- 临床药房 临床药房
- 药物经济学 药物经济学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性自身免疫性疾病,影响胃肠道,显著降低患者的生活质量.
- 在IBD管理中越来越多地使用生物药物和Janus激酶抑制剂等先进疗法,提高了门诊药剂师的作用.
- 门诊药剂师现在是诊所和医院管理IBD患者的医疗保健团队的关键成员.
研究的目的:
- 追溯评估免疫药剂师对炎症性肠病患者的门诊服务的有效性和成本效益.
- 评估药剂师干预对治疗结果的影响,包括干预接受率和患者改善.
主要方法:
- 在2019年1月至2020年12月期间进行了一项回顾性研究,其中包括来自IBD专业门诊的患者.
- 收集的数据包括药物干预的数量 (处方建议和询问) 以及医生接受的比例.
- 患者改善率和药剂师门诊服务的成本效益是关键终点,涉及139名患者和579项评估.
主要成果:
- 在门诊药剂师组的352项干预中,医生接受了341项 (96.9%),而在发药组的74项 (73.0%) 中,医生接受了54项 (p<0.0001).
- 药物干预的整体改善率为93.5%.
- 免疫药剂师门诊显示出显著的成本效益,估计为44,068,000日元.
结论:
- 免疫药剂师门诊服务在管理炎症性肠道疾病方面非常有效,医生接受提出的干预措施的比例很高.
- 这些专门的药房服务对IBD患者的药物治疗结果作出了积极的贡献.
- 临床药剂师和医生在IBD门诊服务中的整合对于优化患者护理和实现成本有效的治疗策略至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147


